Lexicon Pharmaceuticals, Inc. Stock Nasdaq
Stocks
US5288721047
Biotechnology & Medical Research
| Market Cap | 893M 778M 717M 675M 1.26B 84.15B 1.27B 8.53B 3.31B 41.47B 3.35B 3.28B 144B | P/E 2026 * |
-12.8x | P/E 2027 * | -10.6x |
|---|---|---|---|---|---|
| Enterprise Value | 893M 778M 717M 675M 1.26B 84.15B 1.27B 8.53B 3.31B 41.47B 3.35B 3.28B 144B | EV / Sales 2026 * |
23.4x | EV / Sales 2027 * | 44.3x |
| Free-Float |
98.45% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Lexicon Pharmaceuticals, Inc.
| 1 day | +7.56% |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Exton
CEO | Chief Executive Officer | 56 | 2024-07-07 |
Scott Coiante
DFI | Director of Finance/CFO | 59 | 2025-01-01 |
Michael Davies
CTO | Chief Tech/Sci/R&D Officer | - | 2025-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Ray Debbane
CHM | Chairman | 71 | 2012-02-26 |
| Director/Board Member | 67 | 2007-08-27 | |
Philippe Amouyal
BRD | Director/Board Member | 67 | 2007-07-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.56% | +0.99% | - | - | 906M | |
| -2.23% | -1.65% | +61.34% | +109.10% | 56.24B | |
| +4.60% | +5.82% | +56.35% | +43.04% | 43.76B | |
| -1.44% | +1.51% | -12.94% | -19.24% | 23.32B | |
| -2.69% | -0.95% | -3.68% | +379.00% | 21.34B | |
| +3.22% | +2.94% | +24.02% | -35.05% | 15.75B | |
| -0.67% | +0.65% | +14.86% | -39.22% | 15.6B | |
| -1.01% | -2.97% | +27.42% | +171.92% | 13.18B | |
| +3.07% | +5.43% | +21.37% | - | 12.01B | |
| +4.95% | +13.49% | +121.11% | +249.05% | 11.87B | |
| Average | +1.54% | +2.12% | +34.43% | +107.33% | 23.68B | |
| Weighted average by Cap. | +0.53% | +1.53% | +38.49% | +98.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 38.17M 33.25M 30.65M 28.83M 53.94M 3.6B 54.32M 365M 142M 1.77B 143M 140M 6.14B | 20.15M 17.56M 16.19M 15.23M 28.48M 1.9B 28.68M 193M 74.79M 936M 75.65M 74.02M 3.24B |
| Net income | -66.94M -58.32M -53.76M -50.57M -94.61M -6.31B -95.27M -640M -248M -3.11B -251M -246M -10.78B | -88.26M -76.9M -70.89M -66.68M -125M -8.32B -126M -843M -328M -4.1B -331M -324M -14.21B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
